Best Penny Stocks To Trade #5: Citius Pharmaceuticals Inc.
Finally, Citius Pharmaceuticals Inc. (CTXR – Free Report) has been on the move in a similar manner as InspireMD. During the later part of the 4th quarter, shares of CTXR stock hit fresh 52-week lows of $0.40. However, since then shares have turned around for the time being.
Why has Citius made such a move? Well, let’s look at what’s out there. First, the last new release was regarding a positive outcome to interim futility analysis for its Phase 3 trial. It involves its Mino-Lok treatment. Based on this analysis of data the recommendation of the Data Monitoring Committee was to proceed with the current trial as planned.
Here’s what could allude to reasons behind a move early this year. Topline data from the superior efficacy interim analysis is expected in the first half of 2020. This is the next major milestone in the Mino-Lok trial and seeing as we’re in the first half, technically, could this last move be related to that topic? No matter the case, CTXR stock has managed to gain more traction toward the end of the week.
